Type 2 Diabetes trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Type 2 Diabetes. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month18 studies across 8 companies, in the next 180 days.
August 2026 4
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| NVO | Novo Nordisk A/S | A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral NeuropathyNCT06797869Change in weekly average Pain Intensity-Numerical Rating Scale (PI-NRS) | Phase 2 | Active, not recruiting | 2026-08-21 | in 1 d | 2025-12-05 |
| LLY | Eli Lilly and Company | Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)NCT06260722Change from Baseline in Hemoglobin A1c (HbA1c) (%) | Phase 3 | Active, not recruiting | Aug 2026 | ≤ 11 d | 2026-04-13 |
| LLY | Eli Lilly and Company | A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes MellitusNCT07313813Percentage of Fasting Participants with Lack of Gastric Content Retention Post-Solid Test Meal | Phase 1 | Active, not recruiting | Aug 2026 | ≤ 11 d | 2026-04-16 |
| NVO | Novo Nordisk A/S | A Two-armed Real-world Study of Ozempic (OW Semaglutide) to Evaluate Its Adherence and Persistence Compared With Other Anti-diabetic Drugs Among Adult T2DM Patients in ChinaNCT07456774observationalTime to 3P major adverse cardiovascular events | — | Enrolling by invitation | 2026-08-31 | in 11 d | 2026-05-20 |
September 2026 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| SNY | Sanofi | iGlarLixi CGM Study in Chinese T2D Individuals After OADsNCT06671587Superiority of mean change in the percentage of TIR [3.9-10.0 mmol/L (70-180 mg/dL)] | Phase 4 | Recruiting | 2026-09-18 | in 29 d | 2026-03-17 |
| LLY | Eli Lilly and Company | A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesNCT05536804Percent Change from Baseline in Renal Sinus Fat Content (MRI) | Phase 2 | Active, not recruiting | Sep 2026 | ≤ 41 d | 2026-05-08 |
October 2026 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| NVO | Novo Nordisk A/S | Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in KoreaNCT05714683observationalNumber (Incidence) of adverse events (AEs) | — | Not yet recruiting | 2026-10-30 | in 71 d | 2025-12-05 |
| LLY | Eli Lilly and Company | Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)NCT06297603Change from Baseline in Hemoglobin A1c (HbA1c) (%) | Phase 3 | Active, not recruiting | Oct 2026 | ≤ 72 d | 2026-07-20 |
November 2026 4
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| AMGN | Amgen | A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes MellitusNCT07160257Change from Baseline in M-value from Hyperinsulinemic-euglycemic Clamp at Week 25 | Phase 1 | Active, not recruiting | 2026-11-15 | in 87 d | 2026-06-12 |
| LLY | Eli Lilly and Company | A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal InsulinNCT07215312Change from Baseline in Glucose Time in Range Between 70 and 180 mg/dL Inclusive (Non-Inferiority Analysis) | Phase 2 | Active, not recruiting | Nov 2026 | ≤ 102 d | 2026-07-13 |
| LLY | Eli Lilly and Company | A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes MellitusNCT07299084Percentage of Participants with Lack of Gastric Content Retention Post-Solid Test Meal | Phase 1 | Active, not recruiting | Nov 2026 | ≤ 102 d | 2026-05-19 |
| NVO | Novo Nordisk A/S | Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in KoreaNCT05689372observationalNumber (incidence) of adverse events (AEs) | — | Enrolling by invitation | 2026-11-30 | in 102 d | 2026-05-05 |
December 2026 6
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| PODD | Insulet Corporation | Evaluation of the Fully Closed Loop Omnipod® System in Type 2 DiabetesNCT07521475HbA1c | Not applicable | Recruiting | 2026-12-24 | in 126 d | 2026-08-03 |
| 068270.KS | Celltrion | Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and MetforminNCT07093476HbA1c | Phase 3 | Recruiting | Dec 2026 | ≤ 133 d | 2025-08-11 |
| GAIA | Gaia AG | Evaluating a Digital Intervention for Alleviating Diabetes-specific Emotional Distress in Adults Living With T2DMNCT06529965Diabetes-specific emotional distress | Not applicable | Active, not recruiting | Dec 2026 | ≤ 133 d | 2026-06-15 |
| LLY | Eli Lilly and Company | A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or TirzepatideNCT06897475Change from Baseline in Hemoglobin A1c (HbA1c) | Phase 2 | Recruiting | Dec 2026 | ≤ 133 d | 2026-08-06 |
| LLY | Eli Lilly and Company | A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 DiabetesNCT06945406Number of Participants with One or More Serious Adverse Event(s) (SAEs) and Adverse Event(s) (AEs) Considered by the Investigator to be Related to Study Drug Administration | Phase 1 | Recruiting | Dec 2026 | ≤ 133 d | 2026-03-11 |
| MNOV | MediciNova | MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and HypertriglyceridemiaNCT05464784Mean change in controlled attenuation parameter (CAP) score by sound-based elastography at Week 24 | Phase 2 | Active, not recruiting | 2026-12-31 | in 133 d | 2026-02-05 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Type 2 Diabetes
most recently updated first1,756 studies match. Showing the first 100 of 1,756 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 DiabetesNCT06945419Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration | Phase 1 | Completed | Drug: LY4086940, Placebo, LY4086940 | Healthy, Overweight, Obesity, Type 2 Diabetes | 219 | 2025-04-23 | 2026-08-05actual | — | 2026-08-19 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 DiabetesNCT07668336Change from Baseline in Hemoglobin A1c (HbA1c) | Phase 3 | Not yet recruiting | Drug: Orforglipron, Dulaglutide | Diabetes Mellitus, Type 2 | 170 | Sep 2026 | Mar 2030 | ≤ 1,319 d | 2026-08-19 |
| ALNY | Alnylam Pharmaceuticals | $30.6B | A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DMNCT06845202Part A: Frequency of Adverse Events (AEs) | Phase 1/2 | Active, not recruiting | Drug: ALN-4324, Placebo | Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mellitus (T2DM) | 105 | 2025-03-03 | 2027-08-31 | in 376 d | 2026-08-14 |
| NVO | Novo Nordisk A/S | — | SEMA-CardioDiab HUNGARY: A Research Study to Understand the Effects of Oral Semaglutide on Blood Sugar Levels, Weight, and Cardiovascular Risk in People With Type 2 Diabetes Patients in HungaryNCT06269120observationalGlycated haemoglobin (HbA1c ) reduction greater than or equal to (≥) 0.5%-point and body weight reduction ≥ 5% | — | Completed | Drug: Oral Semaglutide | Type 2 Diabetes | 243 | 2024-09-30 | 2026-05-05actual | — | 2026-08-13 |
| NVO | Novo Nordisk A/S | — | A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 DiabetesNCT06326047Change in Glycated haemoglobin (HbA1c) | Phase 2 | Completed | Drug: NNC0519-0130, Placebo, Trizepatide | Diabetes Mellitus, Type 2 | 299 | 2024-03-18 | 2025-09-19actual | — | 2026-08-13 |
| NVO | Novo Nordisk A/S | — | A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 DiabetesNCT06542874Change in HbA1c | Phase 2 | Completed | Drug: NNC0487-0111 subcutanous, Placebo (NNC0487-0111 subcutanous), NNC0487-0111 oral, Placebo (NNC0487-0111 oral) | Type 2 Diabetes (T2D) | 448 | 2024-08-07 | 2025-10-01actual | — | 2026-08-13 |
| NVO | Novo Nordisk A/S | — | A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People With Type 2 DiabetesNCT07271251Change in glycated haemoglobin (HbA1c). | Phase 3 | Completed | Drug: Oral semaglutide | Type 2 Diabetes | 267 | 2025-12-01 | 2026-06-29actual | — | 2026-08-13 |
| ALNY | Alnylam Pharmaceuticals | $30.6B | A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes MellitusNCT07465224Change from Baseline in M-value | Phase 2 | Recruiting | Drug: ALN-4324, Placebo | Type 2 Diabetes Mellitus (T2DM) | 24 | 2026-01-15 | 2027-05-28 | in 281 d | 2026-08-12 |
| PFE | Pfizer | $155.3B | A Clinical Trial Comparing the Efficacy and Safety of Exubera® and Lantus®NCT00391027results2009-10-21Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 | Phase 4 | Completed | Drug: Insulin Glargine (Lantus®), Inhaled Human Insulin (Exubera®) | Diabetes Mellitus, Type 2 | 261 | Dec 2006 | Aug 2008actual | — | 2026-08-11 |
| PFE | Pfizer | $155.3B | This Study Is To Determine If Inhaled Insulin Is Effective In Treating Type 2 Diabetes MellitusNCT00418522results2009-09-04Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 26 for the Per Protocol (PP) Population | Phase 4 | Completed | Drug: Insulin glargine, Inhaled Insulin (Exubera) | Diabetes Mellitus, Type 2 | 413 | Mar 2007 | Aug 2008actual | — | 2026-08-11 |
| NVO | Novo Nordisk A/S | — | A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin BeforeNCT04760626results2025-08-26Change in Glycated Haemoglobin (HbA1c) | Phase 3 | Completed | Drug: Insulin icodec, Insulin Glargine 100U/mL, Insulin Degludec, Insulin Glargine 300U/mL | Diabetes Mellitus, Type 2 | 1,085 | 2021-03-01 | 2022-08-12actual | — | 2026-08-11 |
| PROK | Prokidney | $85M | Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney DiseaseNCT05099770Surrogate / Intermediate Efficacy Endpoint -eGFR Slope | Phase 3 | Active, not recruiting | Biological: Renal Autologous Cell Therapy (REACT/ rilparencel) · Procedure: Sham Comparator | Type 2 Diabetes Mellitus, Chronic Kidney Diseases | 685 | 2022-01-05 | Dec 2029 | ≤ 1,229 d | 2026-08-11 |
| NVO | Novo Nordisk A/S | — | A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 DiabetesNCT06340854results2026-07-02Change in Glycated Haemoglobin (HbA1c) | Phase 3 | Completed | Drug: Insulin icodec, Insulin glargine | Diabetes, Type 2 | 412 | 2024-04-19 | 2025-05-08actual | — | 2026-08-11 |
| DXCM | DexCom, Inc. | $33.8B | CONtiNuous glucosE Monitoring (CGM) in People wiTh Type 2 Diabetes Not on InsulinNCT06601166To assess the benefit on glycemic control and safety from baseline to week 26 using CGM versus RC. | Not applicable | Active, not recruiting | Device: CGM | Type 2 Diabetes | 283 | 2024-08-15 | 2026-05-13actual | — | 2026-08-11 |
| NVO | Novo Nordisk A/S | — | A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults With Type 2 DiabetesNCT07112339Change in glycated haemoglobin (HbA1c) | Phase 4 | Recruiting | Drug: Insulin icodec, Basal insulin analogues | Diabetes Mellitus, Type 2 | 586 | 2025-08-15 | 2028-03-23 | in 581 d | 2026-08-11 |
| NVO | Novo Nordisk A/S | — | A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)NCT05035082results2026-08-10Change in Glycated Haemoglobin (HbA1c) | Phase 4 | Completed | Drug: semaglutide, oral glucose-lowering medications (commercially available) | Diabetes Mellitus, Type 2 | 1,018 | 2021-09-01 | 2025-06-18actual | — | 2026-08-10 |
| NVO | Novo Nordisk A/S | — | A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 DiabetesNCT07415954Change in glycated haemoglobin (HbA1c) (week 16) | Phase 2 | Recruiting | Drug: NNC0662-0419, Semaglutide, Placebo | Diabetes Mellitus, Type 2 | 270 | 2026-04-17 | 2027-09-03 | in 379 d | 2026-08-10 |
| GPCR | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | $11.5B | A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)NCT07654374Percent change in body weight from Baseline | Phase 3 | Recruiting | Drug: aleniglipron, aleniglipron, aleniglipron, Placebo | Obesity, Overweight, Chronic Weight Management, Type2 Diabetes Mellitus | 1,100 | 2026-07-17 | Sep 2028 | ≤ 772 d | 2026-08-10 |
| NVO | Novo Nordisk A/S | — | A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 DiabetesNCT07668388UBT251: Change in glycated haemoglobin (HbA1c) | Phase 2 | Recruiting | Drug: UBT251, UBT251 Placebo, Semaglutide, Semaglutide Placebo | Diabetes Mellitus, Type 2 | 300 | 2026-06-22 | 2027-10-04 | in 410 d | 2026-08-10 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)NCT06739122Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration | Phase 3 | Recruiting | Drug: Dulaglutide | Type 2 Diabetes | 55 | 2025-01-10 | Dec 2027 | ≤ 498 d | 2026-08-07 |
| BMEA | Biomea Fusion Inc. | $98M | Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic TargetsNCT07502495To demonstrate that icovamenib 100 mg once daily for 12 weeks is superior to placebo for glycemic control | Phase 2 | Recruiting | Drug: icovamenib 100mg, Placebo | Type 2 Diabetes | 60 | 2026-03-27 | Mar 2027 | ≤ 223 d | 2026-08-07 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or TirzepatideNCT06897475Change from Baseline in Hemoglobin A1c (HbA1c) | Phase 2 | Recruiting | Drug: LY3457263, Placebo | Type 2 Diabetes | 240 | 2025-03-28 | Dec 2026 | ≤ 133 d | 2026-08-06 |
| NVO | Novo Nordisk A/S | — | A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 DiabetesNCT03811561Presence of at least 3 steps Early Treatment Diabetic Retinopathy Study (ETDRS) subject level progression. | Phase 3 | Active, not recruiting | Drug: Semaglutide, Placebo (semaglutide) | Diabetes Mellitus, Type 2 | 1,500 | 2019-05-08 | 2027-11-07 | in 444 d | 2026-08-04 |
| AZN | AstraZeneca | — | A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes MellitusNCT07662044Change from baseline in Hemoglobin A1c (HbA1c) | Phase 3 | Recruiting | Drug: Elecoglipron, Dapagliflozin, Elecoglipron-matched placebo, Dapagliflozin-matched placebo | Type 2 Diabetes Mellitus | 800 | 2026-07-06 | 2028-07-14 | in 694 d | 2026-08-04 |
| AZN | AstraZeneca | — | A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes MellitusNCT07662109Change from baseline in Hemoglobin A1c (HbA1c) | Phase 3 | Recruiting | Drug: Elecoglipron, Dapagliflozin, Elecoglipron-matched placebo, Dapagliflozin-matched placebo | Type 2 Diabetes Mellitus | 2,000 | 2026-07-06 | 2028-07-05 | in 685 d | 2026-08-04 |
| AZN | AstraZeneca | — | A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background DapagliflozinNCT07662135Change from baseline in Hemoglobin A1c (HbA1c) | Phase 3 | Recruiting | Drug: Elecoglipron, Placebo | Type 2 Diabetes Mellitus, Type 2 Diabetes With Chronic Kidney Disease | 900 | 2026-07-06 | 2028-07-13 | in 693 d | 2026-08-04 |
| AZN | AstraZeneca | — | A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background InsulinNCT07664553Change from baseline in Hemoglobin A1c (HbA1c) | Phase 3 | Recruiting | Drug: Elecoglipron, Placebo | Type 2 Diabetes Mellitus | 600 | 2026-07-08 | 2028-05-23 | in 642 d | 2026-08-04 |
| NVO | Novo Nordisk A/S | — | Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With CagrilintideNCT07220759Relative change in body weight | Phase 3 | Active, not recruiting | Drug: Cagrilintide, Placebo (matched to Cagrilintide) | Overweight, Obesity, Type 2 Diabetes | 330 | 2025-11-05 | 2027-05-12 | in 265 d | 2026-08-03 |
| PODD | Insulet Corporation | $10.3B | Evaluation of the Fully Closed Loop Omnipod® System in Type 2 DiabetesNCT07521475HbA1c | Not applicable | Recruiting | Device: Device: Omnipod M System with study CGM, Standard Therapy plus study CGM | Type 2 Diabetes Mellitus | 350 | 2026-04-30 | 2026-12-24 | in 126 d | 2026-08-03 |
| PODD | Insulet Corporation | $10.3B | Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 SystemNCT07579702Time in Range 70-180 mg/dL | Not applicable | Recruiting | Device: Omnipod 5 System, Omnipod 6 System | Type 2 Diabetes Mellitus, Type 1 Diabetes Mellitus | 200 | 2026-05-13 | 2027-02-22 | in 186 d | 2026-08-03 |
| AMGN | Amgen | $229.9B | A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes MellitusNCT07590193Number of Treatment-Emergent Adverse Events (TEAEs) | Phase 1 | Recruiting | Drug: AMG 127, Placebo | Diabetes Mellitus, Type 2 | 162 | 2026-06-11 | 2027-10-02 | in 408 d | 2026-08-03 |
| LLY | Eli Lilly and Company | $1.15T | A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 DiabetesNCT06993792Number of Participants Allocated to Each Study | Phase 3 | Active, not recruiting | Drug: Orforglipron, Placebo | Obesity, Overweight, Type 2 Diabetes | 1,400 | 2025-05-15 | Aug 2027 | ≤ 376 d | 2026-07-31 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or OverweightNCT05929079Percent Change from Baseline in Body Weight | Phase 3 | Completed | Drug: Retatrutide, Placebo | Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea | 1,152 | 2023-07-11 | 2026-06-16actual | — | 2026-07-30 |
| NVO | Novo Nordisk A/S | — | A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose WeightNCT07564414Relative change in body weight | Phase 3 | Recruiting | Drug: Cagrisema, Semaglutide | Obesity, Type 2 Diabetes | 2,500 | 2026-05-21 | 2028-02-23 | in 552 d | 2026-07-30 |
| GUBRA.CO | Gubra A/S | — | A Three-part First-in-human Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB-UCN2 in Healthy Lean and Obese Participants and Participants With T2DNCT07702890Number of Treatment Emergent Adverse Events | Phase 1/2 | Recruiting | Drug: GUB-UCN2, Placebo | Obesity, Type 2 Diabetes | 188 | Jul 2026 | Dec 2028 | ≤ 864 d | 2026-07-29 |
| NVO | Novo Nordisk A/S | — | A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) ParticipantsNCT07532863observationalCardiometabolic profile: Systolic blood pressure at baseline | — | Recruiting | Other: No treatment given | Diabetes Mellitus, Type 2 | 400 | 2026-03-13 | 2027-03-27 | in 219 d | 2026-07-28 |
| 068270.KS | Celltrion | $30.7B | Phase I Study to Evaluate the Pharmacokinetics and Safety After Co-administration of L03RD1 and L03RD2 or Administration of L03TD1 in Healthy VolunteersNCT07533539AUCt | Phase 1 | Completed | Drug: L03RD1, L03RD2, L03TD1 | Type 2 Diabetes Mellitus (T2DM) | 48 | 2026-05-09 | 2026-05-28actual | — | 2026-07-28 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)NCT07400653Percent Change from baseline in body weight | Phase 3 | Active, not recruiting | Drug: PF-08653944 · Other: Placebo | Obesity, Overweight and/or Obesity, Overweight, Diabetes, Type 2, Type 2 Diabetes | 1,044 | 2026-02-24 | 2027-10-12 | in 418 d | 2026-07-27 |
| BSX | Boston Scientific Corporation | $73.1B | Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)NCT07639684Serious Adverse Events | Not applicable | Not yet recruiting | Device: ESG with OverStitch | Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30) | 50 | Feb 2027 | May 2029 | ≤ 1,015 d | 2026-07-24 |
| AZN | AstraZeneca | — | iCaReMe Global Registry: Multinational Real-world Evidence in Cardiorenal and Metabolic DiseasesNCT03549754observational1. Age of particpants | — | Recruiting | — | Type 2 Diabetes, Hypertension, Chronic Kidney Disease, Heart Failure | 35,000 | 2018-02-17 | 2030-12-31 | in 1,594 d | 2026-07-22 |
| SNY | Sanofi | — | A Randomized Controlled Trial to Compare the Glycemic Control, With or Without the Connected Solution, of Adult Type 2 Diabetic Participants on Basal Insulin in TaiwanNCT05684341Change from baseline in HbA1c at Week 24 | Not applicable | Completed | Combination product: Connected Solution with H2S app which connects with blood glucose meter (BGM) | Type 2 Diabetes Mellitus | 200 | 2023-02-17 | 2024-06-18actual | — | 2026-07-21 |
| LLY | Eli Lilly and Company | $1.15T | Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)NCT06297603Change from Baseline in Hemoglobin A1c (HbA1c) (%) | Phase 3 | Active, not recruiting | Drug: Retatrutide, Placebo | Type 2 Diabetes | 320 | 2024-03-15 | Oct 2026 | ≤ 72 d | 2026-07-20 |
| NVO | Novo Nordisk A/S | — | A Research Study of a New Medicine, NNC9733-0001, in Healthy Participants and Participants With Type 2 DiabetesNCT07270731Number of treatment emergent adverse events (TEAEs) | Phase 1 | Recruiting | Drug: NNC9733-0001, Placebo | Healthy Volunteer, Type 2 Diabetes | 60 | 2025-11-25 | 2028-03-15 | in 573 d | 2026-07-20 |
| NVO | Novo Nordisk A/S | — | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or BothNCT06534411Change in Glycated Haemoglobin (HbA1c) | Phase 3 | Completed | Drug: Cagrilintide, Semaglutide, Tirzepatide | Diabetes Mellitus, Type 2 | 1,023 | 2024-11-05 | 2026-06-02actual | — | 2026-07-17 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 DiabetesNCT07215559Percent Change from Baseline in Body Weight | Phase 2 | Recruiting | Drug: Macupatide, Eloralintide, Macupatide Placebo, Eloralintide Placebo | Obesity, Overweight, Diabetes Mellitus, Type 2 | 200 | 2025-10-16 | Mar 2027 | ≤ 223 d | 2026-07-17 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY3502970 in Japanese Participants With Type 2 Diabetes MellitusNCT05086445results2026-07-16Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration | Phase 1 | Completed | Drug: LY3502970, Placebo | Diabetes Mellitus, Type 2 | 62 | 2021-11-12 | 2022-09-05actual | — | 2026-07-16 |
| AZN | AstraZeneca | — | A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes MellitusNCT07662213Change from baseline in Hemoglobin A1c (HbA1c) | Phase 3 | Recruiting | Drug: Elecoglipron, Semaglutide | Type 2 Diabetes Mellitus | 1,200 | 2026-07-06 | 2028-05-23 | in 642 d | 2026-07-14 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal InsulinNCT07215312Change from Baseline in Glucose Time in Range Between 70 and 180 mg/dL Inclusive (Non-Inferiority Analysis) | Phase 2 | Active, not recruiting | Drug: LY3938577, Degludec | Diabetes Mellitus, Type 2 | 100 | 2025-10-13 | Nov 2026 | ≤ 102 d | 2026-07-13 |
| SNY | Sanofi | — | A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes MellitusNCT06716424Percentage of participants with treatment emergent adverse events (TEAEs) including serious adverse events (SAEs) | Phase 4 | Completed | Drug: iGlarLixi (insulin glargine/lixisenatide) | Type 2 Diabetes | 105 | 2025-01-06 | 2026-06-12actual | — | 2026-07-10 |
| NVO | Novo Nordisk A/S | — | A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 DiabetesNCT07357740Change in glycated haemoglobin (HbA1c) | Phase 2 | Withdrawnsponsor's stated reason: The study is withdrawn due to strategic reasons. | Drug: CagriSema, Placebo CagriSema | Diabetes Mellitus, Type 2 | 0 | 2026-08-27 | 2027-08-25 | in 370 d | 2026-07-09 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 DiabetesNCT04255433results2026-07-08Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse Cardiovascular Events Death From Cardiovascular Causes, Myocardial Infarction (MI) or Stroke] | Phase 3 | Completed | Drug: Tirzepatide, Dulaglutide | Type 2 Diabetes Mellitus | 13,299 | 2020-05-29 | 2025-06-12actual | — | 2026-07-08 |
| NVO | Novo Nordisk A/S | — | A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorNCT06065540CagriSema (dose 1) versus semaglutide (dose 1): Change in glycated haemoglobin (HbA1c) | Phase 3 | Completed | Drug: Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide | Type 2 Diabetes Mellitus | 2,734 | 2023-09-27 | 2025-11-19actual | — | 2026-07-08 |
| ARWR | Arrowhead Pharmaceuticals | $12.4B | A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes MellitusNCT06937203Number of Participants with Treatment-Emergent Adverse Events (TEAEs) | Phase 1/2 | Recruiting | Drug: ARO-ALK7, Placebo | Obesity, Diabetes Mellitus, Type 2 | 150 | 2025-05-09 | Feb 2027 | ≤ 192 d | 2026-07-08 |
| AZN | AstraZeneca | — | A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical StudiesNCT07606066observationalPatient demographics | — | Recruiting | Other: Procedure: assessment | Type 2 Diabetes | 2,150 | 2026-05-06 | 2027-03-31 | in 223 d | 2026-07-07 |
| AMGN | Amgen | $229.9B | Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)NCT07684144Percent Change in Body Weight from Baseline of the Parent Trial (20210184) | Phase 3 | Not yet recruiting | Drug: Maridebart Cafraglutide, Placebo | Obesity, Overweight, Diabetes Mellitus, Type 2 | 950 | 2026-07-29 | 2027-12-26 | in 493 d | 2026-07-06 |
| DXCM | DexCom, Inc. | $33.8B | Evaluation of Basal Insulin Initialization and Titration in People With Type 2 Diabetes Wearing a Dexcom G6 SensorNCT07681375Measurement of participant safety while using the DexBasal Study System | Phase 1 | Active, not recruiting | Drug: Basal insulin · Device: Dexcom Continuous Glucose Monitoring (CGM) | Type 2 Diabetes | 45 | 2023-04-11 | 2026-01-16actual | — | 2026-07-02 |
| LLY | Eli Lilly and Company | $1.15T | A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 DiabetesNCT06010004results2026-06-30Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Phase 3 | Completed | Drug: Orforglipron | Type 2 Diabetes | 401 | 2023-09-28 | 2025-06-05actual | — | 2026-06-30 |
| NVO | Novo Nordisk A/S | — | Prevalence and Overlap of Cardiovascular, Kidney, and Metabolic Diseases in Korea: A Population-based StudyNCT07673822observationalProportion of participants with obesity (BMI ≥25 kilograms per square meter (kg/m^2)) | — | Enrolling by invitation | Other: No treatment given | Diabetes Mellitus, Type 2, Obesity, Chronic Kidney Disease, Cardiovascular Risk | 800,000 | 2026-06-08 | 2026-08-03 | — | 2026-06-29 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan FastingNCT07613307Change from Baseline in Hemoglobin A1C (HbA1c) | Phase 3 | Not yet recruiting | Drug: Orforglipron | Diabetes Mellitus, Type 2, Diabetes Melletus, Glucose Metabolism Disorders, Metabolic Disorders, Nutritional and Metabolic Diseases, Endocrine System Diseases, Feeding Behavior, Behavior, Fasting, Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide Receptors, Receptors, G-Protein-Coupled, Receptors, Cell Surface, Membrane Proteins, Proteins, Receptors, Peptide | 130 | Jul 2026 | May 2027 | ≤ 284 d | 2026-06-23 |
| NVO | Novo Nordisk A/S | — | A Research Study to Evaluate the Safety of NNC1679-0001 When Given to Healthy Participants and Participants With T2DMNCT07570992Number of Treatment-Emergency Adverse Events (TEAEs) | Phase 1 | Recruiting | Drug: NNC1679-0001, Placebo | Healthy Volunteers, Diabetes Mellitus, Type 2 | 58 | 2026-05-04 | 2028-06-25 | in 675 d | 2026-06-22 |
| NVO | Novo Nordisk A/S | — | Research Study to Examine Blood Sugar Control, Treatment Satisfaction and Adherence in People With Type 2 Diabetes After Switching From Daily Basal Insulin to Once-weekly Insulin IcodecNCT07658417observationalChange in glycated haemoglobin (HbA1c) | — | Not yet recruiting | Drug: Insulin icodec | Diabetes Mellitus, Type 2 | 216 | 2026-06-15 | 2027-12-01 | in 468 d | 2026-06-22 |
| LLY | Eli Lilly and Company | $1.15T | A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to HypoglycemiaNCT06982846Time-to-Event of Recovery of Plasma Glucose (PG) Concentration from 48 Milligram per Deciliter (48 mg/dL) to 70 mg/dL (tPG_nadir-70 mg/dL) | Phase 1 | Completed | Drug: Retatrutide, Placebo | Type 2 Diabetes Mellitus | 80 | 2025-06-06 | 2026-05-04actual | — | 2026-06-18 |
| GAIA | Gaia AG | $36M | Evaluating a Digital Intervention for Alleviating Diabetes-specific Emotional Distress in Adults Living With T2DMNCT06529965Diabetes-specific emotional distress | Not applicable | Active, not recruiting | Behavioral: covivio | Glucose Metabolism Disorders (Including Diabetes Mellitus), Metabolic Disease, Endocrine System Diseases, Diabetes Mellitus, Type 2 | 250 | 2024-10-09 | Dec 2026 | ≤ 133 d | 2026-06-15 |
| BMEA | Biomea Fusion Inc. | $98M | Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based TherapyNCT07502508To demonstrate that icovamenib 100 mg once daily for 12 weeks is superior to placebo for glycemic control | Phase 2 | Recruiting | Drug: icovamenib 100 mg, Placebo | Type 2 Diabetes | 60 | 2026-04-30 | Jun 2027 | ≤ 314 d | 2026-06-15 |
| NVO | Novo Nordisk A/S | — | A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3)NCT04795531results2024-12-04Change in Glycated Haemoglobin (HbA1c) | Phase 3 | Completed | Drug: Insulin icodec, Placebo insulin icodec, Insulin degludec, Placebo insulin degludec | Diabetes Mellitus, Type 2 | 588 | 2021-03-24 | 2022-06-23actual | — | 2026-06-12 |
| NVO | Novo Nordisk A/S | — | A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)NCT05259033results2025-01-17Change From Baseline in Glycosylated Haemoglobin (HbA1c) | Phase 3 | Completed | Drug: IcoSema, Semaglutide 1 mg | Diabetes Mellitus, Type 2 | 683 | 2022-04-11 | 2023-12-13actual | — | 2026-06-12 |
| PFE | Pfizer | $155.3B | A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DMNCT06897202Percent change from baseline in body weight at Week 28 (Day 197) | Phase 2 | Completed | Drug: MET097 Injection, Placebo | Obesity in Diabetes, Type 2 Diabetes Mellitus (T2DM) | 133 | 2025-03-14 | 2025-12-29actual | — | 2026-06-12 |
| AMGN | Amgen | $229.9B | A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes MellitusNCT07160257Change from Baseline in M-value from Hyperinsulinemic-euglycemic Clamp at Week 25 | Phase 1 | Active, not recruiting | Drug: Maridebart cafraglutide, Placebo | Type 2 Diabetes Mellitus | 56 | 2025-08-05 | 2026-11-15 | in 87 d | 2026-06-12 |
| NVO | Novo Nordisk A/S | — | Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Semaglutide in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry DataNCT04572165observationalOccurrence of first time malignant neoplasm of pancreas | — | Completed | Drug: Ozempic®, Active Comparator, Rybelsus® | Diabetes Mellitus, Type 2 | 194,928 | 2021-01-26 | 2025-11-25actual | — | 2026-06-11 |
| NVO | Novo Nordisk A/S | — | A Study to Test How a New Long-acting Insulin Works in the Body of Patients With Type 2 Diabetes During Exercise and Prolonged FastingNCT06288412Time below range, glucose less than (<) 3.0 millimoles per liter (mmol/L) (54 milligrams per deciliter [mg/dL]) within 24 hours after start of exercise (TBR3.0mmol/L,exe) | Phase 1 | Completed | Drug: Insulin icodec, Insulin degludec | Diabetes Mellitus, Type 2 | 30 | 2024-02-26 | 2025-03-10actual | — | 2026-06-08 |
| NVO | Novo Nordisk A/S | — | A Research Study to Examine Blood Sugar Control, Treatment Satisfaction and Adherence in People With Type 2 Diabetes After Switching From Daily Basal Insulin to Once-weekly Insulin IcodecNCT07632404observationalChange in glycated haemoglobin (HbA1c) | — | Not yet recruiting | Drug: Insulin icodec | Diabetes Mellitus, Type 2 | 214 | 2026-06-05 | 2027-12-01 | in 468 d | 2026-06-08 |
| NVO | Novo Nordisk A/S | — | A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 DiabetesNCT04560998results2025-07-08Change in Maximum Walking Distance on a Constant Load Treadmill Test | Phase 3 | Completed | Drug: Semaglutide, Placebo (semaglutide) | Diabetes Mellitus, Type 2, Peripheral Arterial Disease | 792 | 2020-10-01 | 2024-06-05actual | — | 2026-06-05 |
| NVO | Novo Nordisk A/S | — | A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)NCT06269107Change in glycated haemoglobin (HbA1c) | Phase 3 | Completed | Drug: IcoSema, Insulin glargine | Type 2 Diabetes | 485 | 2024-02-15 | 2025-05-27actual | — | 2026-06-05 |
| NVO | Novo Nordisk A/S | — | A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 DiabetesNCT05813912results2026-06-03Change in Glycated Haemoglobin (HbA1c) | Phase 3 | Completed | Drug: Insulin Icodec, Semaglutide | Diabetes Mellitus, Type 2 | 148 | 2023-09-22 | 2025-04-14actual | — | 2026-06-03 |
| CL | Colgate Palmolive | $72.9B | Evaluate the Efficacy of an Oral Health Behavioral Intervention in People With DiabetesNCT07619729Dental Claims | Phase 4 | Enrolling by invitation | Behavioral: Diabetes Oral Health Program · Drug: Stannous Fluoride Dentifrice, Cetylpyridinium Chloride (CPC) and Zinc Lactate Mouthwash | Diabetes Type 2, Periodontal Disease, Caries | 10,000 | 2026-05-26 | 2028-01-02 | in 500 d | 2026-06-03 |
| NVO | Novo Nordisk A/S | — | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 DiabetesNCT07282613Change in glycated haemoglobin (HbA1c) | Phase 3 | Not yet recruiting | Drug: CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I) | Diabetes Mellitus, Type 2 | 80 | 2026-08-04 | 2029-09-07 | in 1,114 d | 2026-05-28 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY3502970 in Participants With Type 2 DiabetesNCT04426474results2026-05-26Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug | Phase 1 | Completed | Drug: LY3502970, Placebo | Diabetes Mellitus, Type 2 | 68 | 2020-10-08 | 2021-07-12actual | — | 2026-05-26 |
| TNDM | Tandem Diabetes Care, Inc. | $1.7B | A Randomized Trial Evaluating Control-IQ+ Technology in Adults With Type 2 DiabetesNCT05785832results2025-06-03HbA1c | Not applicable | Completed | Device: t:slim X2 insulin pump with Control-IQ+ technology and Dexcom G6 CGM, Standard Therapy plus continuous glucose monitoring (CGM) | Type 2 Diabetes Treated With Insulin | 319 | 2023-06-01 | 2024-09-24actual | — | 2026-05-22 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During RamadanNCT06635057Change from Baseline in Hemoglobin A1c (HbA1c) | Phase 4 | Completed | Drug: Tirzepatide | Type 2 Diabetes | 166 | 2024-10-11 | 2026-04-15actual | — | 2026-05-22 |
| NVO | Novo Nordisk A/S | — | A Two-armed Real-world Study of Ozempic (OW Semaglutide) to Evaluate Its Adherence and Persistence Compared With Other Anti-diabetic Drugs Among Adult T2DM Patients in ChinaNCT07456774observationalTime to 3P major adverse cardiovascular events | — | Enrolling by invitation | — | Type 2 Diabetes | 100,000 | 2026-02-13 | 2026-08-31 | in 11 d | 2026-05-20 |
| NVO | Novo Nordisk A/S | — | Post-Marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ozempic®NCT04469855observationalNumber of adverse events (AEs) | — | Completed | Drug: semaglutide | Diabetes Mellitus, Type 2 | 3,217 | 2020-07-27 | 2025-05-12actual | — | 2026-05-19 |
| LLY | Eli Lilly and Company | $1.15T | A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes MellitusNCT07299084Percentage of Participants with Lack of Gastric Content Retention Post-Solid Test Meal | Phase 1 | Active, not recruiting | Drug: Tirzepatide | Diabetes Mellitus, Type 2, Overweight, Obesity | 40 | 2026-01-14 | Nov 2026 | ≤ 102 d | 2026-05-19 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or ObesityNCT07438444Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration | Phase 4 | Recruiting | Drug: Tirzepatide | Diabetes Mellitus, Type 2, Obesity, Overweight | 344 | 2026-02-27 | Oct 2027 | ≤ 437 d | 2026-05-19 |
| 068270.KS | Celltrion | $30.7B | Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With MetforminNCT06571591HbA1c | Phase 3 | Completed | Drug: CT-L03 Group 1, CT-L03 Group 2, Placebo, Empagliflozin, Metformin | T2DM | 606 | 2024-08-27 | 2026-04-16actual | — | 2026-05-15 |
| NVO | Novo Nordisk A/S | — | A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)NCT05514535results2026-05-11Change in Glycated Haemoglobin (HbA1c) [Noninferiority] | Phase 3 | Completed | Drug: Semaglutide, Insuline glargine U100 (reduced), Insuline glargine U100 (titrated) | Diabetes Mellitus, Type 2, Obesity | 573 | 2022-08-29 | 2025-03-05actual | — | 2026-05-11 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesNCT05536804Percent Change from Baseline in Renal Sinus Fat Content (MRI) | Phase 2 | Active, not recruiting | Drug: Tirzepatide, Placebo | Overweight, Obesity, Chronic Kidney Disease, Type 2 Diabetes, T2D | 140 | 2023-02-08 | Sep 2026 | ≤ 41 d | 2026-05-08 |
| NVO | Novo Nordisk A/S | — | Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in KoreaNCT05689372observationalNumber (incidence) of adverse events (AEs) | — | Enrolling by invitation | Drug: Semaglutide | Diabetes Mellitus, Type 2 | 600 | 2026-02-02 | 2026-11-30 | in 102 d | 2026-05-05 |
| PODD | Insulet Corporation | $10.3B | An Evaluation of the Omnipod® M System in Adults With Type 2 DiabetesNCT07276776Percent of time in hypoglycemic range <70mg/dL | Not applicable | Completed | Device: Omnipod M system | Type 2 Diabetes Mellitus | 40 | 2025-12-12 | 2026-03-30actual | — | 2026-05-05 |
| NVO | Novo Nordisk A/S | — | A Study Using Flash Glucose Measurements for a New Once-weekly Insulin (Insulin Icodec) in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 9)NCT05823948results2026-04-30Change in Glycosylated Haemoglobin (HbA1c) | Phase 3 | Completed | Drug: Insulin Icodec | Diabetes Mellitus, Type 2 | 51 | 2023-04-11 | 2024-03-06actual | — | 2026-04-30 |
| NVO | Novo Nordisk A/S | — | A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose WeightNCT05649137results2026-04-27Relative Change in Body Weight | Phase 3 | Completed | Drug: Semaglutide, Semaglutide, Placebo | Obesity, Diabetes Mellitus, Type 2 | 512 | 2023-01-04 | 2024-10-28actual | — | 2026-04-27 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise AloneNCT05971940results2026-04-22Change From Baseline in HbA1c | Phase 3 | Completed | Drug: Orforglipron, Placebo | Type 2 Diabetes | 559 | 2023-08-09 | 2025-04-03actual | — | 2026-04-22 |
| NVO | Novo Nordisk A/S | — | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorNCT06221969Change in glycated haemoglobin (HbA1c) | Phase 3 | Completed | Drug: Cagrilintide, Semaglutide, Tirzepatide | Type 2 Diabetes | 1,024 | 2024-01-16 | 2026-03-04actual | — | 2026-04-22 |
| AZN | AstraZeneca | — | A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With Type 2 Diabetes MellitusNCT07433062Mean glucose levels | Phase 1 | Suspendedsponsor's stated reason: Safety issue was identified in the Phase2b D7860C00006 study, evaluating AZD6793 in moderate to very severe COPD participants. D7860C00005 study is temporary halted to amend the design to reflect changes implemented in the ongoing D7860C00006 study | Drug: AZD6793, AZD6793 Placebo | Type 2 Diabetes Mellitus | 28 | 2026-01-14 | 2026-06-18 | — | 2026-04-22 |
| SENS | Senseonics, Inc. | $459M | Gemini Study: A Prospective, Multicenter Evaluation of Performance and Safety of the Eversense Gemini System With Flash Glucose Measurement FeatureNCT07386340System agreement (15/15%, 20/20%, 30/30%, and 40/40%) for paired sensor FGM and reference measurements post-insertion for reference glucose values from 40-400 mg/dL. | Not applicable | Recruiting | Device: Continuous Glucose Monitoring System | Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | 80 | 2025-12-29 | Dec 2027 | ≤ 498 d | 2026-04-21 |
| SENS | Senseonics, Inc. | $459M | ROME GS System StudyNCT07518004Mean absolute relative difference (MARD) for paired sensor and reference measurements post-insertion. | Not applicable | Recruiting | Device: Continuous Glucose Monitoring System | Diabetes, Diabetes Melletus, Type 1, Diabetes Mellitus, Type 2 | 60 | 2026-02-12 | Aug 2028 | ≤ 742 d | 2026-04-21 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 DiabetesNCT06972472Change from Baseline in Hemoglobin A1c (HbA1c) | Phase 3 | Active, not recruiting | Drug: Orforglipron, Placebo | Obesity, Overweight, Type 2 Diabetes | 600 | 2025-05-19 | Aug 2027 | ≤ 376 d | 2026-04-20 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular RiskNCT05803421Time to First Occurrence of Any Major Adverse Cardiovascular Event (MACE-4) [Myocardial Infarction (MI), Stroke, Hospitalization for Unstable Angina, or Cardiovascular (CV) Death] | Phase 3 | Completed | Drug: Orforglipron, Insulin Glargine | Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease | 2,749 | 2023-04-03 | 2026-03-16actual | — | 2026-04-17 |
| LLY | Eli Lilly and Company | $1.15T | A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes MellitusNCT07313813Percentage of Fasting Participants with Lack of Gastric Content Retention Post-Solid Test Meal | Phase 1 | Active, not recruiting | Drug: Dulaglutide | Type 2 Diabetes Mellitus (T2DM) | 20 | 2025-12-29 | Aug 2026 | ≤ 11 d | 2026-04-16 |
| LLY | Eli Lilly and Company | $1.15T | Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)NCT06260722Change from Baseline in Hemoglobin A1c (HbA1c) (%) | Phase 3 | Active, not recruiting | Drug: Retatrutide, Semaglutide | Diabetes Mellitus, Type 2 | 1,250 | 2024-02-21 | Aug 2026 | ≤ 11 d | 2026-04-13 |
| NVO | Novo Nordisk A/S | — | An Indian Post Marketing Study of Mealtime Insulin, Fiasp®, to Evaluate Its Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical PracticeNCT03987802observationalAdverse Events (AEs) | — | Completed | Drug: Faster-acting insulin aspart | Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | 42 | 2021-01-20 | 2022-06-28actual | — | 2026-04-09 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Type 2 Diabetes is matched — 22 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Diabetes Mellitus, Type 2
- Type 2 Diabetes Mellitus
- Type 2 Diabetes
- Diabetes Mellitus Type 2
- Type 2 Diabetes Mellitus (T2DM)
- Diabetes Mellitus, Non-Insulin-Dependent
- Diabetes Type 2
- Type II Diabetes Mellitus
- Diabetes, Type 2
- Type 2 Diabetes Treated With Insulin
- Type II Diabetes
- Type2 Diabetes
- T2D
- T2DM
- Healthy Volunteers Type 2 Diabetes
- Type 2 Diabetes Mellitus (T2D)
- Type-2 Diabetes
- Type2 Diabetes Mellitus
- Healthy Volunteers (Diabetes Mellitus, Type 2)
- Healthy Volunteers Diabetes Mellitus, Type 2
- T2DM (Type 2 Diabetes Mellitus)
- Type 2 Diabetes (T2D)
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Type 2 Diabetes” (a text search, wider than this page)